Group 1: A-Share Buyback Events - During the period from February 23, 2026, to March 1, 2026, a total of 6 listed companies announced shareholder buyback plans, with the average buyback amount as a percentage of total market capitalization being 0.18% for Aidi Pharmaceutical, 1.09% for Binhua Co., 0.04% for Tongce Medical, 0.07% for Huaneng Hydropower, 1.69% for Biyinlefen, and 0.80% for Conch Cement [1][8][11]. Group 2: Key Companies of Interest - **Biyinlefen**: The company announced its first buyback and the controlling shareholder plans to buy back more than 1% of shares, with an amount between 100 million and 200 million RMB, reflecting confidence in the company's long-term prospects as a leading high-end apparel group focused on golf lifestyle [2][13]. - **Aidi Pharmaceutical**: The controlling shareholder plans to buy back 0.18% of shares, with an expected turnaround from loss to profit and a high growth rate in net profit forecasted [2][14][15]. - **Conch Cement**: The controlling shareholder plans to buy back 0.80% of shares, with a buyback amount between 7 billion and 14 billion RMB, indicating recognition of the company's long-term value in the cement industry [3][20][21]. Group 3: Management Buyback Announcements - From February 23, 2026, to March 1, 2026, 9 listed companies announced management buyback plans, with the only company exceeding 0.01% of total market capitalization being Sruy New Materials [11].

Core Viewpoint - Eddie Pharmaceuticals reported a significant revenue increase of 72.49% in 2025, driven by rising income from innovative anti-HIV drugs and operational data from its subsidiary, Nanda Pharmaceuticals. The company's losses narrowed from 141 million yuan in 2024 to 19.73 million yuan in 2025, marking an 86.02% reduction in loss margin [1][2]. Group 1: Financial Performance - The company achieved a revenue of 721 million yuan in 2025, with a year-on-year growth of 72.49% [2]. - The loss for 2025 was reduced to 19.73 million yuan from 141 million yuan in 2024, indicating a significant improvement in financial health [2]. - Eddie Pharmaceuticals turned a profit in operating income for the first time, reporting 47.74 million yuan in 2025 [2]. Group 2: Anti-HIV Drug Segment - Revenue from innovative anti-HIV drugs is projected to reach 285 million yuan in 2025, representing a 90.34% increase year-on-year [3]. - The anti-HIV drugs are expected to account for 39.53% of the company's total revenue in 2025 [3]. - The sales of anti-HIV new drugs nearly doubled from 150 million yuan in 2024 to 285 million yuan in 2025 [3]. Group 3: Nanda Pharmaceuticals Contribution - Nanda Pharmaceuticals, a subsidiary, is expected to generate 300 million yuan in revenue for 2025, reflecting a 227.38% increase year-on-year [4]. - Eddie Pharmaceuticals has made several acquisitions to increase its stake in Nanda Pharmaceuticals, enhancing its control and management efficiency [4][6]. - The strategic focus on Nanda Pharmaceuticals aims to solidify Eddie Pharmaceuticals' position in the human protein sector, particularly in the production of urokinase and other biopharmaceuticals [5][6].

Core Viewpoint - Jiangsu Aidi Pharmaceutical Group Co., Ltd. has successfully renewed the inclusion of two innovative HIV drugs, Ainovelin Tablets and Ainomir Tablets, in the National Medical Insurance Directory for 2025, reflecting the recognition of their clinical value and innovation by the National Healthcare Security Administration [1][5]. Drug Information - **Ainovelin Tablets**: - Drug Name: Ainovelin Tablets - Medical Insurance Payment Standard: 24.15 yuan per tablet - Composition: Ainovelin 0.15g, Lamivudine 0.3g, Tenofovir Disoproxil Fumarate 0.3g - Registration Category: Class 1 chemical drug - Drug Classification: Antiviral drug for HIV infection - Insurance Category: Category B - Dosage Form: Tablet - Exclusive Variety: Yes - Limited Payment Scope: For HIV infection only - Agreement Validity: January 1, 2026, to December 31, 2027 [1][5]. - **Ainomir Tablets**: - Drug Name: Ainomir Tablets - Registration Category: Class 1 chemical drug - Drug Classification: Antiviral drug for HIV infection - Insurance Category: Category B - Dosage Form: Tablet - Exclusive Variety: Yes - Limited Payment Scope: For HIV infection only - Agreement Validity: January 1, 2026, to December 31, 2027 [1][3]. Clinical Efficacy - **Ainovelin Tablets**: - A novel non-nucleoside reverse transcriptase inhibitor (NNRTI) approved in June 2021 for treatment of HIV-1 infection in treatment-naive patients. Phase III clinical trials showed comparable antiviral efficacy to the control drug Efavirenz, with significantly reduced central nervous system side effects and low rates of liver toxicity and rash [2]. - **Ainomir Tablets**: - A compound formulation that includes two nucleoside reverse transcriptase inhibitors (NRTIs) added to Ainovelin. Approved for domestic sale in December 2022, it has shown sustained viral suppression and comparable safety to imported drugs in head-to-head Phase III trials. The drug has demonstrated advantages in cardiovascular metabolic safety indicators [3][4]. Impact on the Company - The renewal of the two innovative HIV drugs in the National Medical Insurance Directory is expected to enhance their sales and market promotion, significantly benefiting the company's operational development. The company aims to establish a marketing system for domestic HIV innovative drugs and provide diverse treatment options for patients, addressing the urgent need for upgraded HIV treatment in China [5].

Group 1 - Heng Rui Pharmaceutical has 9 drugs included in the national medical insurance directory for the first time, with an estimated total sales of approximately 8.66 billion yuan for 2024 and 7.55 billion yuan for the first three quarters of 2025 [5] - Junshi Biosciences' products Tuoyi® and Junshida® have been added to the national medical insurance directory, enhancing patient affordability and market promotion [6] - Huadong Medicine's subsidiary has products included in the national medical insurance and commercial insurance innovative drug directories, expected to aid in market promotion [7] Group 2 - Aidi Pharmaceutical's two innovative HIV drugs have successfully renewed their inclusion in the national medical insurance directory, with specific reimbursement prices set [8] - Fuxing Pharmaceutical has multiple products newly included in the national medical insurance directory, which is anticipated to positively impact future performance [9] - Weichuang Biotechnology's product has been included in the national medical insurance directory, which is expected to enhance market promotion and sales [10] Group 3 - Muxi Co., Ltd. announced a final online issuance rate of 0.03348913% after the mechanism was activated, with a total of 22.83 million shares issued [2] - Doushan New Materials reached a consensus on production reduction in the BOPET industry, although the sustainability of long-term price increases remains uncertain [2] - Guanglian Aviation's controlling shareholder has had the detention lifted, allowing normal operations to resume [3] Group 4 - Jiangjian Co., Ltd. clarified that it bears no obligations for any overdue financial products related to its controlling shareholder, confirming normal operations [4] - Tian Ci Materials' controlling shareholder has committed not to reduce holdings, holding 34.35% of the shares [13] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [14]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - In H1 2025, the company achieved revenue of 362 million yuan, representing a year-on-year increase of 100.19%, and a net profit of 9 million yuan, up 120.23% year-on-year, marking a turnaround to profitability [4] - The gross margin for H1 2025 was 65.58%, an increase of 16.83 percentage points, while the net margin was 7.31%, up 32.40 percentage points [4] - The company is well-positioned in the HIV treatment and prevention market, with significant growth expected from its innovative drugs [5] Financial Summary - Revenue projections for 2025-2027 are 737 million, 1.037 billion, and 1.237 billion yuan respectively, with net profit forecasts of -2 million, 44 million, and 88 million yuan [4][7] - The company's P/S ratios for the next three years are projected at 10.2, 7.2, and 6.1 times [4][7] - The company reported a sales expense ratio of 34.32% and a management expense ratio of 12.19% in H1 2025 [4] Business Segments - The revenue from human-derived protein crude products was 149 million yuan, while revenue from HIV drugs was 129 million yuan, reflecting a 58.49% increase [4] - The company has a comprehensive HIV research pipeline, with promising results from clinical trials of its drug ACC017 [5]

Core Viewpoint - The HIV drug market in China is experiencing rapid growth due to an increasing number of patients, expanding insurance coverage, and rising payment capabilities among the affected population, with a projected market size of 5.836 billion yuan in 2024, reflecting a year-on-year growth of 30.2% [1][16]. Industry Overview - HIV drugs are antiviral medications aimed at treating AIDS, which is caused by the human immunodeficiency virus (HIV) that attacks the immune system [2]. - As of the end of 2024, there are approximately 1.355 million reported living HIV/AIDS patients in China, with 749,800 being HIV-infected and 605,200 being AIDS patients [1][4]. Market Dynamics - The Chinese HIV drug market is expected to maintain a growth rate of over 20% from 2021 to 2024, driven by the increasing number of patients and the expansion of medical insurance coverage [16]. - The self-paid drug market is projected to reach 3.787 billion yuan in 2024, growing by 47.5% year-on-year, while the free drug market is expected to be 2.049 billion yuan, with a growth of 7% [18]. Competitive Landscape - Gilead and GSK dominate the Chinese HIV drug market, holding a combined market share of 90%, while local companies like Frontier Biopharma and Aidi Pharmaceutical have a smaller market presence of less than 10% [22]. Development Trends - Future research in the global HIV drug market will focus on developing new drugs with better efficacy and safety, exploring new drug targets, and investigating new treatment methods such as gene therapy and immunotherapy [24].